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Autonomic functionPreviously, we found that the nitrate synthesized from glycerin, 2-nitrate-1,3-dibuthoxypropan (NDBP),
increased NO levels in rat aortic smooth muscle cells, inducing vasorelaxation in mesenteric artery. However,
its effects on blood pressure and heart rate as well as on autonomic function were not investigated. This study
evaluated the action of NDBP on these cardiovascular parameters in spontaneously hypertensive (SHR) and
Wistar Kyoto (WKY) rats. We found that NDBP causes a biphasic response: hypotension and bradycardia
followed by hypertension and tachycardia in WKY and SHR rats. Atropine (2 mg/kg) blunted the hypotension
induced by NDBP (15 mg/kg) in WKY and SHR (−75±9 vs −12±3 mm Hg, n=6; −101±6 vs −7±
2 bpm, n=6; respectively, pb0.05) and the pressor response to the compound was potentiated. Furthermore,
vagotomy reduced the bradycardia in WKY and SHR (−136±8 vs −17±2, n=4, pb0.05; −141±9 vs
−8±2, n=6, pb0.05). Moreover, hexamethonium (30 mg/kg) reduced both bradycardia (−278±23 vs
−48±3 in WKY; −285±16 vs −27±19 in SHR, n=4; pb0.05) and pressor response (28±8 vs −9±
5-WKY, n=6; 42±7 vs−19±8-SHR, n=5; pb0.05). In addition, administration of methylene blue (4 mg/kg)
attenuated the hypotensive and bradycardic responses to the NDBP in all groups. In conclusion, NDBP induces bra-
dycardia by direct vagal stimulation and pressor response by increasing sympathetic outﬂow to the periphery.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Hypertension is amultifactorial disorder,which in amajority of cases
is a result of changes in several mechanisms that regulate blood pres-
sure. Studies suggest that changes in reﬂex control of blood pressure
are involved in the development and maintenance of hypertension
(Smith et al., 2004). Endothelial alterations with enhanced generation
of contractile substances, reactive oxygen species (ROS) and reduced
formation or activity of nitric oxide (NO) also may be involved in the
pathogenesis of hypertension (Marín and Rodrigues-Martinez, 1997).
NO is an important molecule in the modulation of cardiovascular
function participating in the maintenance of normal vascular tone and
as a neuromodulator, altering the sympathetic and parasympathetic
outﬂow to the periphery (Zanzinger, 1999; Schmitt and Dirsch, 2009).
The role of NO in the progress of changes caused by cardiovascular
diseases is classically reported in the literature; therefore, NO is a poten-
tial therapeutic target in hypertension (Rajapakse and Mattson, 2009).
Drugs which mimic the role of this molecule in the body such as NO
donors are known to act in the treatment of hypertension. Therefore,
a new NO donor, the 2-nitrate-1,3-dibuthoxypropan (NDBP), waseral University of Paraiba, P.O.
83 3216 7511.
evier OA license.newly synthetized (Fig. 1). NDBP is a compound obtained from the syn-
thetic route of glycerin, considered a “waste” in the biodiesel produc-
tion process (Santos, 2009). Recently, our research group showed the
vascular effects produced by NDBP (Franca-Silva et al., 2012). In the
mesenteric artery from normotensive rats, NDBP evoked potent
vasorelaxant effect through NO generation and activation of the sCG/
cGMP/PKG pathway. Furthermore, the release kinetic of NOwas similar
to other NO donors such as glyceryl trinitrate (GTN) and sodium nitro-
prusside (SNP) (Franca-Silva et al., 2012). However the effects induced
byNDBP on blood pressure, heart rate and autonomic function have not
been investigated.
The evidence that hypertension is associated with changes in auto-
nomic nervous system and the fact that NOmay exert a direct inﬂuence
on autonomic control of blood pressure, reducing the deleterious effect
of hypertension, led us to evaluate the effects of theNO donor, NDBP, on
the autonomic balance of spontaneously hypertensive rats (SHR), and
its control normotensive Wistar-Kyoto rats (WKY).
2. Material and methods
2.1. Animals
MaleWistar-Kyoto and spontaneously hypertensive rats (250–300 g),
housed under controlled conditions of temperature (21±1 °C) and
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Fig 1. Structural formula of NDBP.
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PURINA, Brazil) ad libitum were used in all experiments. All the experi-
mental procedures were conducted in accordance with the Institutional
Animal Care and Use Committee of the Federal University of Paraiba
(CEPA 0209/10).
2.2. NDBP preparation
NDBPwas dissolved in a mixture of saline solution and chremophor
and diluted to the desired concentrations with saline solution as previ-
ously described (Franca-Silva et al., 2012).
2.3. Surgical procedures and protocols
Intra-aortic blood pressure was recorded using the technique
described by Braga (2010). Brieﬂy, under ketamine (75 mg/kg, i.p.)
and xylazine (10 mg/kg, i.p.) anesthesia, the rats were ﬁtted with poly-
ethylene catheters inserted into the lower abdominal aorta and inferior
vena cava through left femoral artery and vein, respectively. Both cath-
eters were ﬁlled with heparinized saline, tunneled subcutaneously,
exteriorized and sutured at the dorsal surface of the neck. Twenty-four
hours after the surgical procedures, experiments were performed in
conscious rats. The arterial catheter was connected to a pre-calibrated
pressure transducer coupled to an acquisition system (PowerLab,
ADInstruments, Unit 13, 22 Lexington Drive, Bella Vista, NSW, Australia)
connected to a computer installed with LabChart 5.0 software.
2.4. Assessment of cardiovascular effects of NDBP
One day after the surgical procedures, blood pressure and heart
rate were evaluated after the randomly administration of different
doses of NDBP (1, 5, 10, 15 and 20 mg/kg, i.v.) in conscious rats.
2.5. Evaluation of the parasympathetic activity in NDBP-induced
cardiovascular responses
In order to investigate the contribution of parasympathetic activity
on hypotension promoted by NDBP, atropine (2 mg/kg, i.v.), a musca-
rinic blocker, was injected in normotensive and hypertensive conscious
rats, and the effect of NDBPwas evaluated before and after (15 min) the
blockade.
In other set of experiments, to assess whether NDBP induces bra-
dycardia due to a central or peripheral action, WKY and SHR rats were
submitted to vagotomy. Firstly, the rats were anesthetized with keta-
mine and xylazine (75 and 10 mg/kg, i.p., respectively) and afterstabilization of the baseline parameters, NDBP was administered
before and after (15 min) the bilateral section of the vagus nerve.
The responses to the compound were evaluated before and after
this surgical procedure.
2.6. Evaluation of sympathetic activity in the NDBP-induced cardiovascular
responses
In order to investigate the effect of NDBP on the sympathetic
activity, organic nitrate was administered 15 min before and after
ganglionic blockade with hexamethonium (30 mg/kg, i.v.) in WKY
and SHR conscious rats.
2.7. Evaluation of the participation of nitric oxide in the NDBP-mediated
cardiovascular effects
To investigate the effect of NDBP on NO availability, in vivo effects
of NDBP was assessed blocking soluble guanylyl cyclase (sGC), an
intermediate of the NO pathway, with intravenous administration of
methylene blue (4 mg/kg, in bolus) in WKY and SHR conscious rats.
2.8. Statistical analysis
Results are expressed as mean±SEM. Data were analyzed by
“one-way” analysis of variance (ANOVA) followed by a Bonferroni's
post-test for multiple comparisons whenever appropriate. All statisti-
cal analyses were performed using GraphPad Prism (v. 5.0, GraphPad
Software, Inc). Statistical signiﬁcance was deﬁned as pb0.05.
3. Results
3.1. Effects of NDBP on blood pressure (BP) and heart rate (HR) in
conscious rats
Spontaneously hypertensive rats were signiﬁcantly hypertensive
compared with WKY rats (165.8±5.6 vs 105.8±7.8 mm Hg, n=6,
pb0.05, respectively). Fig. 2 (A and C) shows representative tracings
from spontaneously hypertensive and normotensive Wistar-Kyoto
rats illustrating the changes in these parameters after administration
of NDBP. From these results, the dose of NDBP (15 mg/kg) was
chosen to perform the following protocols. Administration of NDBP
(1, 5, 10, 15 and 20 mg/kg) elicited dose-dependent hypotension
(−4±2, −21±6, −54±6, −62±10, −76±8 mm Hg, n=6,
pb0.05) and bradycardia, except in the ﬁrst dose (1±5, −70±26,
−248±10, −240±25,−301±29 bpm, pb0.05) followed by hyper-
tension (5±2, 4±1, 6±2, 5±2, 12±3 mm Hg) and tachycardia
(25±4, 11±10, 55±19, 40±9, 76±16 bpm, pb0.05) in normo-
tensive Kyoto (WKY) rats as illustrated in Fig. 2B. Interestingly, in spon-
taneously hypertensive rats, hypotensive (−8±1, −20±5, −86±4,
−95±5, −118±3 mm Hg, n=6, pb0.05) and bradycardic (−9±8,
−125±37, −252±10, −269±16, −309±18 bpm, n=6, pb0.05)
responses exhibited were signiﬁcantly higher when compared to WKY
rats. This increase was also found in hypertensive (9±2, 15±3, 50±
5, 57±4, 60±8 mm Hg, pb0.05) and tachycardic (30±10, 45±9,
49±11, 76±15, 110±19 bpm, pb0.05) responses (Fig. 2D).
3.2. Effects of NDBP after parasympathetic blockade
The administration of NDBP (15 mg/kg) caused hypotension asso-
ciated with profound bradycardia in all animals. The blockade of
muscarinic receptors with atropine (2 mg/kg) abolished bradycardia
induced by NDBP (15 mg/kg) in WKY (−265±25 vs. −48±7 bpm,
n=6, pb0.05) and SHR (−255±9 vs −25±10 bpm, pb0.05,
n=6). In addition, atropine blunted hypotension induced by NDBP
in WKY (−75±9 mm Hg vs −12±3 mm Hg, n=6, pb0.05) as
well as in SHR rats (−101±6 vs −7±2 bpm, n=6, pb0.05) and
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Fig. 2. Effect of NDBP on mean arterial pressure (MAP, mm Hg) and heart rate (HR, bpm) in normotensive Wistar Kyoto (WKY) and spontaneously hypertensive (SHR) rats. Rep-
resentative tracings from normotensive Wistar Kyoto (WKY) (A) and spontaneously hypertensive rat (SHR) (C) illustrating the changes in pulse arterial pressure (PAP, mm Hg),
mean arterial pressure (MAP, mm Hg), and heart rate (HR, bpm) in response to administration of different doses of the NDBP (black arrows). Data from the group of WKY (B) and
SHR (D) rats, illustrating the primary (black bars) and secondary responses (white bars) at different doses of NDBP. Values are means±S.E.M. ⁎pb0.05 versus baseline.
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65±4 mm Hg-WKY; 33±10 vs 82±6 mm Hg-SHR; pb0.05) as
shown in Fig. 3. The acute administration of atropine induced a slight
increase in heart rate without signiﬁcantly altering blood pressure
(data not shown).
3.3. Cardiovascular effects elicited by NDBP after vagotomy
To further investigate the parasympathetic activity induced by
NDBP, using a different experimental protocol, vagotomy was per-
formed. Representative tracings fromWKY and SHR rats show changes
in blood pressure and heart rate elicited by NDBP before and after
vagotomy as shown in Fig. 4 (A and C). Interestingly, vagotomy
produced a large reduction in the NDBP-induced bradycardia in both
WKY (−136±8 vs −17±2 bpm, n=4, pb0.05) and SHR rats
(−141±9 vs−8±2 bpm, n=6, pb0.05). After vagotomy, the hypo-
tensive response was attenuated in SHR (−66±8 vs −34±
11 mm Hg, pb0.05) as well as in WKY animals (−59±11 vs −35±
9 mm Hg) as shown in Fig. 4 (B and D).
3.4. Effects of NDBP after ganglionic blockade
The acute administration of hexamethonium (30 mg/kg, i.v.)
produced inhibition of the NDBP-induced pressor response (28±8 vs−9±5 mm Hg-WKY, n=6; 42±7 vs −19±8 mm Hg-SHR, n=5;
pb0.05). In relation to HR, there was a reduction in bradycardia in
both animal models (−278±23 vs −48±3 bpm-WKY; −285±16
vs −27±19 bpm-SHR, n=4; pb0.05). The remaining hypotension
(−23±3 and −13±10 mm Hg, in WKY and SHR rats, respectively)
can be attributed to the vascular effect elicited by NDBP (Fig. 5) as
described previously by Franca-Silva et al. (2012).3.5. Effects of NDBP after sGC blockade
To evaluate nitric oxide release in the response induced by admin-
istration of NDBP (15 mg/kg, i.v.), hypotension and bradycardic
responses were analyzed before and after acute infusion of soluble
guanylyl cyclase inhibitor, methylene blue (4 mg/kg). Representative
tracings are presented in Fig. 2 (A and C). In WKY rats both hypo-
tension and bradycardic effects were reduced (−82±6 vs −57±
7 mm Hg, n=6 and −322±14 vs −272±11 bpm, n=6, respec-
tively, pb0.05). Similar results were found in SHR regarding hypoten-
sive (−95±8 vs −70±4 mm Hg, pb0.05, n=2) and bradycardic
effects (−291±12 vs −235±6 bpm, pb0.05, n=5) as illustrated
in Fig. 6 (B and D). The administration of methylene blue caused a
sudden and transient increase in blood pressure without changing
heart rate (data not shown).
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Fig. 3. Effect of NDBP (15 mg/kg) before and after blockade with atropine (2 mg/kg, i.v.) in normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHR).
Representative tracings from WKY (A) and SHR (C) illustrating the changes in pulse arterial pressure (PAP, mm Hg), mean arterial pressure (MAP, mm Hg), and heart rate (HR,
bpm) in response to administration of NDBP before and after atropine. Group data indicating the effect of NDBP (15 mg/kg) before (black bars) and after (white bars) muscarinic
blockade in WKY (B) and SHR (D). Values are means±S.E.M. ⁎pb0.05 versus control hypotensive and bradycardic response. ≠pb0.05 versus control pressor response.
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The main ﬁndings of the present study were that acute intrave-
nous infusion of NDBP, a NO donor, evoked short-lasting responses
comprising initial hypotensive and bradycardic responses followedby pressor and minor tachycardic responses. Bradycardia and hypo-
tension were prevented by muscarinic blockade or by vagal tran-
section. Ganglionic blockade substantially attenuated NDBP-induced
changes in blood pressure and heart rate, and methylene blue, slightly
reduced these changes. InWKY rats, there was no signiﬁcant difference
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values, except in the tachycardia induced by higher dose administered.
Spontaneously hypertensive (SHR) rats are widely used as animal
model for studying essential hypertension in humans, because these
animals have phenotypic characteristics similar to those observed in
human essential hypertension (Pinto et al., 1998). This model is asso-
ciated with increased peripheral vascular resistance, cardiac hyper-
trophy, heart failure, among other pathologies (Fazan et al., 2001).
In addition, the sympathetic nerve activity is signiﬁcantly increased
in relation with their normotensive controls; this justiﬁes, in part,
the fact that the pressor and tachycardia responses were higher in
SHR group. Furthermore, low levels of NO contribute to the develop-
ment and maintenance of hypertension in this model (Wymann et al.,
2003; Portaluppi et al., 2004). Thus, SHR were chosen as a model
to investigate the effect of the NO donor NDBP on the autonomic
nervous system.
Initially, the administration of NDBP in SHR andWKY rats induced
hypotension associated with bradycardia, instead of reﬂex tachycar-
dia as observed in other NO donors such as sodium nitroprusside
and nitroglycerin (Needleman, 1976; Caputi et al., 1980). In order to
evaluate the involvement of parasympathetic activity in response
induced by NDBP, we used atropine (2 mg/kg), which greatly re-
duced the NDBP-induced bradycardia. The reduction of bradycardia
also attenuated the hypotension induced by our nitrate, suggestingthat NDBP reduced the mean blood pressure mainly by reducing the
cardiac output in addition to its effect on the smooth muscle in
the periphery as previously demonstrated by Franca-Silva et al.
(2012).
Contrary to these ﬁndings, previous reports have demonstrated
that NO donors induce relaxation of the vascular smooth muscle
and this effect is responsible for promoting hypotension in rats
(Munhoz et al., 2012; Paulo et al., 2012).In accordance to this ﬁnd-
ings, Herring and Paterson (2001) show the direct inﬂuence of NO
donors on cardiac vagal nerve endings, stimulating the release of ace-
tylcholine (ACh). At the same time, evidence points to the role of NO
in speciﬁc sites of the central nervous system (CNS), increasing para-
sympathetic activity directed to the heart with subsequent bradycar-
dia, which in turn masks the reﬂex tachycardia to the hypotension
(Kishi et al., 2001; Fletcher et al., 2006).
In this context, in order to assess whether the NDBP-induced
bradycardia occurred by a direct action of the compound in the
heart or due to their actions in the CNS, vagotomy was performed
in WKY and SHR animals. This surgical procedure could be visualized
by instantaneous elevation in heart rate of the animals, since the
parasympathetic activity directed to the heart was prevented. The
vagotomy virtually abolished the NDBP-induced bradycardia, demon-
strating that decrease in heart rate occurs due to central action
of NDBP, stimulating the ACh release from vagus nerve. The bilateral
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ination of the bradycardia, conﬁrming the ability of the nitrate to
decline the cardiac output.
The blockade of sGC with methylene blue resulted in a slight
attenuation in hypotension and bradycardia induced by NDBP,
suggesting that the vagomimetic properties of this substance are
also mediated by NO-independent pathway; however, more studies
are needed to clarify this fact.
In a second moment, the NDBP caused hypertension and tachy-
cardia and the ganglionic blockade substantially attenuated these
drug-induced changes, showing that NDBP induces increases in sym-
pathetic outﬂow to periphery while increases the parasympathetic
discharge, conﬁrming the ability of the compound to induce central
effects. Several ﬁndings report that the NO acts in brain sites increas-
ing the parasympathetic activity directly to heart with posterior
bradycardia that masks the reﬂex tachycardia (Kishi et al., 2001;
Fletcher et al., 2006).Residual hypotensive and bradycardic responses were observed
in the presence of hexamethonium (30 mg/kg), suggesting that
there is a modest contribution of the vasorelaxation elicited by NDBP
(Franca-Silva et al., 2012) to produce hypotension in both hyperten-
sive and normotensive rats. The NO exerts vasorelaxation via activa-
tion of guanylate cyclase, increasing intracellular levels of cyclic
guanosine monophosphate (cGMP), resulting in activation of protein
kinase G (PKG), a peptide responsible for the phosphorylation of
several proteins involved on vasorelaxation (Archer et al., 1994;
McDonald and Murad, 1996). This effect can lead to a reduction in
blood pressure, being attenuated by the blockage of soluble guanylyl
cyclase with methylene blue.
These data conﬁrm the reports of Feelisch and Noack (1987)
which stated that the release of NO by organic nitrates is suppressed
by methylene blue, and this inhibition reduces vasodilation mediated
by these compounds and consequently its hypotensive effect. Other
studies have demonstrated that methylene blue is able to attenuate
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34 M.S. França-Silva et al. / Autonomic Neuroscience: Basic and Clinical 171 (2012) 28–35the vasorelaxation, as well as hypotension induced by NO donors
such as SNP, conﬁrming the results found in this study (Wei et al.,
1992; Wang et al., 1995; Crestani, 2008).
Here we report for the ﬁrst time that the new NO donor, NDBP, in-
duces hypotension due to a reduction in cardiac output by direct
vagal stimulation, while causing pressor response by increasing sym-
pathetic outﬂow to the periphery by stimulation of sympathetic out-
ﬂow. These responses depend on the central action of the compound.
There are few substances known to activate cardiac vagal neurons;
therefore, our ﬁndings may encourage new studies to advance the
understanding of the anti-hypertensive effects elicited by NDBP,
which will help to advance the ﬁeld towards clinical trials, consider-
ing that currently used organic nitrates on the clinic are effective in
the treatment of hypertension but exhibit some undesirable effects.
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